BioStock: PHI´s CEO comments on latest advancements

March 29, 2023
Language flag

In 2022, medtech company Phase Holographic Imaging conducted a rights issue that added over 57 million SEK to its coffers. Since then, and with a new focus on regenerative medicine, the company has been attracting more attention, not least by adding the Swiss investor company Altium as a new major shareholder. BioStock reached out to PHI´s CEO, Patrik Eschricht, to learn more about the visions moving forward.

Read the full interview with Patrik Eschricht on biostock.se.

Latest News

Peter Egelberg CEO PHI

Founder and board member subscribes for shares in the ongoing rights issue

Peter Egelberg, founder and Board member of Phase Holographic Imaging PHI AB has notified the Company that he, together with closely related parties, follows Altium SA’s lead by subscribing for shares in the Company’s ongoing fully secured rights issue. The subscription amounts to approximately 300 TSEK.
AndersMansson-web

PHI at Aktieportföljen Live, BioStock and Financial Stockholm

The subscription period in PHI AB’s fully secured rights issue, totalling SEK 64.3 million, is ongoing until 20 December 2024. The Company’s CEO, Anders Månsson, has during the last couple of weeks presented the Company and its future plans. For links to the presentations and the podcast, see below.

Notice of Annual General Meeting in Phase Holographic Imaging PHI AB (publ) 8 January 2025

The shareholders of Phase Holographic Imaging PHI AB (publ), (“the Company”), reg.no. 556542-7811, are hereby invited to attend the general meeting on 8 January 2025 at 15.00 at the Company´s office at Skiffervägen 48 in Lund.
See All News